A trial examining the risks or benefits of drugs that can delay puberty for gender-questioning children is set to begin, and according to Dr. Hilary Cass, the author of a pivotal review, this trial is crucial for reducing potential harm. Dr. Cass has expressed her firm belief that more children will face negative consequences if the trial is not conducted. Her remarks come in response to growing pressure from various campaigners and some lawmakers who are pushing for the cessation of this research initiative, particularly after it was revealed that children as young as 11 could be included in the trial.
This Pathways clinical trial will be managed by researchers at Kings College, London (KCL). They have outlined a minimum age requirement for participants, and significant safeguards have been established to protect them. Dr. Cass recommended this research after her extensive review of gender medicine for children in 2024, which highlighted the lack of solid evidence supporting the use of puberty blockers. While the NHS previously prescribed these blockers for gender care in individuals under 18, a UK-wide indefinite ban was implemented in 2024, halting prescriptions both privately and through the NHS.
Speaking to the BBC, Dr. Cass mentioned that since the ban, “some of the hype about risks have been exaggerated in that we genuinely don’t know if there are harms.” She asserted the trial is “essential” to determine the effectiveness of these drugs. Young participants will be “closely monitored in every respect,” and the medication will be stopped if any concerns are raised. The study aims to assess the drugs’ impact on participants’ physical, social, and emotional wellbeing, including evaluations of bone density, brain function, and fertility.
Dr. Cass warned that without conducting this trial, vulnerable young people may resort to obtaining medications through “unregulated and dangerous routes.” She pointed out that there are currently young individuals seeking testosterone treatment at the age of 11, which is known to have irreversible effects. “It may be that if they were prescribed puberty blockers instead, that would give more time for the therapist to work with them and perhaps come to a different solution than a long-term life on medication,” she added.
It’s important to note that testosterone, a masculinizing hormone, is not permitted for prescription in the UK for children under 16 in the context of gender treatment. Puberty blockers, also referred to as puberty suppressing hormones (PSH), are intended to delay the onset of puberty.
Health Secretary James Murray emphasized the importance of clinical evidence in guiding future decisions regarding these treatments. In Parliament on Monday, he expressed his discomfort with some of the concerns raised but stated, “following the clinical advice, basing future decisions on clinical evidence, is the right way to move forward,” particularly given the robust assurances in place to protect young individuals involved in the trial.
Initially announced in November, the trial was put on hold in February when medical regulators suggested raising the minimum age for participation to 14. However, after thorough discussions, KCL researchers settled on age limits of 11 for birth-registered females and 12 for birth-registered males. Recruitment of children is planned to begin in August, pending ongoing legal challenges.
These legal actions are being pursued by activists who argue the trial is unethical and that minors cannot provide adequately informed consent for participation in a study that could potentially compromise their future fertility. The Bayswater Support Group, representing parents cautious about medical interventions for their gender-questioning children, is among those taking legal action. A spokesperson stated that the trial poses risks of irreversible harm and fails to address “outstanding questions about puberty blockers.”
The Conservative party is advocating for a vote in the House of Commons to allow politicians to weigh in on the matter. Chay Brown, Healthcare Director of trans campaign group TransActual, has welcomed the trial but insists the NHS should reverse the puberty blocker ban and provide “timely and holistic care for all trans people based on informed consent – not the latest moral panic.”
Dr. Cass maintains that this issue should be determined through clinical expertise and scientific inquiry, stressing that young people and their families have been underserved by NHS services for far too long. As the trial prepares to launch amidst legal challenges and public scrutiny, the conversation around puberty blockers and their implications for gender-questioning youth continues to evolve. What will be the outcome of this high-stakes trial? Only time will tell…
Kaynak: Orijinal Haber